Want to create an interactive transcript for this episode?
Podcast: CME
Episode: Ocular to Generalized MG: How and Why the Disease Evolves
Description:
Guest: Vera Bril, MD
Guest: Hans Katzberg, MD
While traditional therapies for generalized myasthenia gravis (gMG) have proven beneficial in the short term, new treatment options with fewer debilitating side effects and longer-term benefit are needed. The emergence of targeted inhibitors of the neonatal Fc receptor (FcRn) have demonstrated in clinical trials and real-world experience that they address both of these needs. Join Drs. Vera Bril, Nicholas Silvestri, and Hans Katzberg as they discuss this exciting new therapeutic option and how it may change the treatment landscape of gMG.